Livre d'or
Signer le livre d'or
Nous avons été enchanté de vous recevoir, et souhaitons que ce plaisir fut partagé.
Laissez nous vos impressions
550602
Messages dans le livre d'or
Nous avons été enchanté de vous recevoir, et souhaitons que ce plaisir fut partagé.
Laissez nous vos impressions
Buster
Vendredi, 15 Mars 2024
By Steven Scheer
TEL AVIV, Feb 20 (Reuters) - Teva Pharmaceutical Industries ?ill r?main a single company for generic and branded drugs, ?nd expects t? ?ee ?ignificant interest in its active pharmaceutical ingredients business t?at it plans to divest, ?ts head ?aid on T?esday.
T?ere h?s been speculation t?at Israel-based Teva - t?e ?orld's largest generic drug maker - ?ould split ?nto two companies handling ?oth the increasingly competitive generics business ?nd its ?wn branded drugs.
H?wever, t?e company will stay unified, and "from an infrastructure point of view, (the two businesses) complement each other incredibly well," Chief Executive Richard Francis ?aid at ? news briefing.
The generics ?ide "allows us to fund a lot of research and development we are doing in our innovative business," he said, citing Teva'? collaborations on R&D with Israeli universities.
?hose partnerships m??n "we don't have to go out and seek funding to drive some of this innovation, which many other companies do."
Teva ?ast month reported strong fourth-quarter earnings ?nd forecast lower profit ?ut high?r sales this y?ar, adding ? deal to sell its API business wo?ld be completed ?n 2025.
Teva sample api f?r testing - dealing ?ith active ingredients contained in medicines - ?s a $1 billion business in an $85 billion global market.
Francis believes t??t a? a standalone business, it ?hould perform "far greater" t?an its annual growth so fa? of 6%.
"Businesses like this don't often come on the market. So I do believe this will affect a significant amount of interest," he said. "That will lead us to get a fair valuation."
Teva is in the process of recovering f?om loss of exclusivity t? ?ts multiple sclerosis drug Copaxone ?nd a spate of lawsuits, and ?s betting th?t a trio of it? branded drugs - Austedo, migraine product Ajovy ?nd schizophrenia drug Uzedy - ?ill h?lp it bounce ?ack.
Teva ?a? several biosimilars - copies ?f high-priced drugs - and net debt is do?n to $16.6 billion.
High debt from a failed acquisition ?n 2017 ha? held Teva b?ck from fu?ther M&A deals, Francis ?aid. ?n the meantim?, Teva ?as been licensing products.
"As our debt goes down, then we have the opportunity to do M&A, but it will be thoughtful and appropriate M&A," ?e sa?d.
Francis ad?ed that since the Israel-Hamas ??r beg?n, Teva has ??en training hundreds of therapists t? help with a trauma crisis ?ikely to affect millions ?f Israelis. (Reporting by Steven Scheer; Editing ?y Kirsten Donovan and Bernadette Baum)
TEL AVIV, Feb 20 (Reuters) - Teva Pharmaceutical Industries ?ill r?main a single company for generic and branded drugs, ?nd expects t? ?ee ?ignificant interest in its active pharmaceutical ingredients business t?at it plans to divest, ?ts head ?aid on T?esday.
T?ere h?s been speculation t?at Israel-based Teva - t?e ?orld's largest generic drug maker - ?ould split ?nto two companies handling ?oth the increasingly competitive generics business ?nd its ?wn branded drugs.
H?wever, t?e company will stay unified, and "from an infrastructure point of view, (the two businesses) complement each other incredibly well," Chief Executive Richard Francis ?aid at ? news briefing.
The generics ?ide "allows us to fund a lot of research and development we are doing in our innovative business," he said, citing Teva'? collaborations on R&D with Israeli universities.
?hose partnerships m??n "we don't have to go out and seek funding to drive some of this innovation, which many other companies do."
Teva ?ast month reported strong fourth-quarter earnings ?nd forecast lower profit ?ut high?r sales this y?ar, adding ? deal to sell its API business wo?ld be completed ?n 2025.
Teva sample api f?r testing - dealing ?ith active ingredients contained in medicines - ?s a $1 billion business in an $85 billion global market.
Francis believes t??t a? a standalone business, it ?hould perform "far greater" t?an its annual growth so fa? of 6%.
"Businesses like this don't often come on the market. So I do believe this will affect a significant amount of interest," he said. "That will lead us to get a fair valuation."
Teva is in the process of recovering f?om loss of exclusivity t? ?ts multiple sclerosis drug Copaxone ?nd a spate of lawsuits, and ?s betting th?t a trio of it? branded drugs - Austedo, migraine product Ajovy ?nd schizophrenia drug Uzedy - ?ill h?lp it bounce ?ack.
Teva ?a? several biosimilars - copies ?f high-priced drugs - and net debt is do?n to $16.6 billion.
High debt from a failed acquisition ?n 2017 ha? held Teva b?ck from fu?ther M&A deals, Francis ?aid. ?n the meantim?, Teva ?as been licensing products.
"As our debt goes down, then we have the opportunity to do M&A, but it will be thoughtful and appropriate M&A," ?e sa?d.
Francis ad?ed that since the Israel-Hamas ??r beg?n, Teva has ??en training hundreds of therapists t? help with a trauma crisis ?ikely to affect millions ?f Israelis. (Reporting by Steven Scheer; Editing ?y Kirsten Donovan and Bernadette Baum)
Edgardo
Vendredi, 15 Mars 2024 | Villeneuve-D'ascq
Perfect piece of work you have done, this site is really cool with good information.
My website zombie escape where u are actually being chased
My website zombie escape where u are actually being chased
Edgardo
Vendredi, 15 Mars 2024 | Villeneuve-D'ascq
Perfect piece of work you have done, this site is really cool with good information.
My website zombie escape where u are actually being chased
My website zombie escape where u are actually being chased
Edgardo
Vendredi, 15 Mars 2024 | Villeneuve-D'ascq
Perfect piece of work you have done, this site is really cool with good information.
My website zombie escape where u are actually being chased
My website zombie escape where u are actually being chased
Edgardo
Vendredi, 15 Mars 2024 | Villeneuve-D'ascq
Perfect piece of work you have done, this site is really cool with good information.
My website zombie escape where u are actually being chased
My website zombie escape where u are actually being chased
Caridad
Vendredi, 15 Mars 2024 | Torregrande
Introduction: Bliss Bites CBD Gummies are quickly becoming a popular choice among individuals looking for a convenient and enjoyable way to incorporate CBD into their daily routine.
my web blog; Order Bliss Bites CBD Gummies
my web blog; Order Bliss Bites CBD Gummies
Caridad
Vendredi, 15 Mars 2024 | Torregrande
Introduction: Bliss Bites CBD Gummies are quickly becoming a popular choice among individuals looking for a convenient and enjoyable way to incorporate CBD into their daily routine.
my web blog; Order Bliss Bites CBD Gummies
my web blog; Order Bliss Bites CBD Gummies
Caridad
Vendredi, 15 Mars 2024 | Torregrande
Introduction: Bliss Bites CBD Gummies are quickly becoming a popular choice among individuals looking for a convenient and enjoyable way to incorporate CBD into their daily routine.
my web blog; Order Bliss Bites CBD Gummies
my web blog; Order Bliss Bites CBD Gummies
Caridad
Vendredi, 15 Mars 2024 | Torregrande
Introduction: Bliss Bites CBD Gummies are quickly becoming a popular choice among individuals looking for a convenient and enjoyable way to incorporate CBD into their daily routine.
my web blog; Order Bliss Bites CBD Gummies
my web blog; Order Bliss Bites CBD Gummies
Nadine
Vendredi, 15 Mars 2024 | Celico
550602
Messages dans le livre d'or